"感染対策の世界市場予測・分析:治療薬、非治療薬" 調査データ


▼当市場調査データについて詳細内容・ご購入は下記ページへ▼
感染対策の世界市場予測・分析:治療薬、非治療薬...市場動向/規模/将来展望...

*** 調査レポートのコンテンツ(一部抜粋)***

LINEで送る

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
• Value chain analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2019
• Market size and forecast 2019-2024
• Market Outlook
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Therapeutic – Market size and forecast 2019-2024
• Non-therapeutic – Market size and forecast 2019-2024
• Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2019-2024
• Europe – Market size and forecast 2019-2024
• Asia – Market size and forecast 2019-2024
• ROW – Market size and forecast 2019-2024
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Technological advances in sterilization equipment
• Rising awareness about infectious diseases
• Growing risk of spreading infections via blood transfusions
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• 3M Co.
• Astellas Pharma Inc.
• Cantel Medical Corp.
• Ecolab Inc.
• Getinge AB
• GlaxoSmithKline Plc
• Merck & Co. Inc.
• Mylan NV
• Pfizer Inc.
• Sanofi
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Vendors: Key offerings
Exhibit 02: Global healthcare market
Exhibit 03: Segments of global healthcare market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ billions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2019
Exhibit 18: Type – Market share 2019-2024 (%)
Exhibit 19: Comparison by type
Exhibit 20: Therapeutic – Market size and forecast 2019-2024 ($ billions)
Exhibit 21: Therapeutic – Year-over-year growth 2020-2024 (%)
Exhibit 22: Non-therapeutic – Market size and forecast 2019-2024 ($ billions)
Exhibit 23: Non-therapeutic – Year-over-year growth 2020-2024 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2019-2024 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America – Market size and forecast 2019-2024 ($ billions)
Exhibit 29: North America – Year-over-year growth 2020-2024 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe – Market size and forecast 2019-2024 ($ billions)
Exhibit 32: Europe – Year-over-year growth 2020-2024 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia – Market size and forecast 2019-2024 ($ billions)
Exhibit 35: Asia – Year-over-year growth 2020-2024 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW – Market size and forecast 2019-2024 ($ billions)
Exhibit 38: ROW – Year-over-year growth 2020-2024 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Ambulatory surgery procedures and visits to hospitals and ambulatory surgery centers in the US, 2010
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: 3M Co. – Vendor overview
Exhibit 50: 3M Co. – Business segments
Exhibit 51: 3M Co. – Organizational developments
Exhibit 52: 3M Co. – Geographic focus
Exhibit 53: 3M Co. – Segment focus
Exhibit 54: 3M Co. – Key offerings
Exhibit 55: Astellas Pharma Inc. – Vendor overview
Exhibit 56: Astellas Pharma Inc. – Business segments
Exhibit 57: Astellas Pharma Inc. – Organizational developments
Exhibit 58: Astellas Pharma Inc. – Geographic focus
Exhibit 59: Astellas Pharma Inc. – Key offerings
Exhibit 60: Cantel Medical Corp. – Vendor overview
Exhibit 61: Cantel Medical Corp. – Business segments
Exhibit 62: Cantel Medical Corp. – Organizational developments
Exhibit 63: Cantel Medical Corp. – Geographic focus
Exhibit 64: Cantel Medical Corp. – Segment focus
Exhibit 65: Cantel Medical Corp. – Key offerings
Exhibit 66: Ecolab Inc. – Vendor overview
Exhibit 67: Ecolab Inc. – Business segments
Exhibit 68: Ecolab Inc. – Organizational developments
Exhibit 69: Ecolab Inc. – Geographic focus
Exhibit 70: Ecolab Inc. – Segment focus
Exhibit 71: Ecolab Inc. – Key offerings
Exhibit 72: Getinge AB – Vendor overview
Exhibit 73: Getinge AB – Business segments
Exhibit 74: Getinge AB – Organizational developments
Exhibit 75: Getinge AB – Geographic focus
Exhibit 76: Getinge AB – Segment focus
Exhibit 77: Getinge AB – Key offerings
Exhibit 78: GlaxoSmithKline Plc – Vendor overview
Exhibit 79: GlaxoSmithKline Plc – Business segments
Exhibit 80: GlaxoSmithKline Plc – Organizational developments
Exhibit 81: GlaxoSmithKline Plc – Geographic focus
Exhibit 82: GlaxoSmithKline Plc – Segment focus
Exhibit 83: GlaxoSmithKline Plc – Key offerings
Exhibit 84: Merck & Co. Inc. – Vendor overview
Exhibit 85: Merck & Co. Inc. – Business segments
Exhibit 86: Merck & Co. Inc. – Organizational developments
Exhibit 87: Merck & Co. Inc. – Geographic focus
Exhibit 88: Merck & Co. Inc. – Segment focus
Exhibit 89: Merck & Co. Inc. – Key offerings
Exhibit 90: Mylan NV – Vendor overview
Exhibit 91: Mylan NV – Product segments
Exhibit 92: Mylan NV – Organizational developments
Exhibit 93: Mylan NV – Geographic focus
Exhibit 94: Mylan NV – Segment focus
Exhibit 95: Mylan NV – Key offerings
Exhibit 96: Pfizer Inc. – Vendor overview
Exhibit 97: Pfizer Inc. – Business segments
Exhibit 98: Pfizer Inc. – Organizational developments
Exhibit 99: Pfizer Inc. – Geographic focus
Exhibit 100: Pfizer Inc. – Segment focus
Exhibit 101: Pfizer Inc. – Key offerings
Exhibit 102: Sanofi – Vendor overview
Exhibit 103: Sanofi – Business segments
Exhibit 104: Sanofi – Organizational developments
Exhibit 105: Sanofi – Geographic focus
Exhibit 106: Sanofi – Segment focus
Exhibit 107: Sanofi – Key offerings
Exhibit 108: Validation techniques employed for market sizing
Exhibit 109: Definition of market positioning of vendors


■ 説 明 ■

Global Infection Control Market: About this market
Technavio’s infection control market analysis considers sales from both therapeutic and non-therapeutic types. Our study also finds the sales of infection control in Asia, Europe, North America, and ROW. In 2019, the therapeutic segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as anti-infectives, such as antibiotics, anti-fungal drugs, and anti-viral drugs, which are used for the prevention and treatment of various infectious diseases will play a significant role in the therapeutic segment to maintain its market position. Also, our global infection control market report looks at factors such as strong incidence of HAIs, increasing number of surgical procedures worldwide, and growing geriatric population. However, concerns regarding the safety of reprocessed instruments, non-compliance toward anti-infective therapy, and complexities involved in storage and transportation of infection control therapeutics may hamper the growth of the infection control industry over the forecast period.
Global Infection Control Market: Overview
Growing geriatric population
The geriatric population is highly susceptible to infectious diseases. The incidence depends on the site of infection and location of the patient, whether a hospital, nursing home or community. Patients residing in nursing homes are mostly affected by pressure ulcer infections, urinary tract infection, and pneumonia. In addition, the chances of acquiring nosocomial infections are high among hospitalized elderly patients. Thus, the growth in the geriatric population will lead to the expansion of the global infection control market at a CAGR of over 4% during the forecast period.
Technological advances in sterilizing equipment
The global infection control market is currently witnessing an increasing interest of vendors to develop effective measures as infection control solutions. Vendors are increasingly exhibiting interest in developing effective measures as infection control solutions. Ultraviolet germicidal irradiation inactivates the pathogen by targeting their nucleic acids. The UV radiation is effective against all forms of pathogens, including bacteria, viruses, and fungi, and it has found widespread use in disinfecting surfaces, water, and air. The infection control systems that are based on these technologies, when used with appropriate care and protocols, can help reduce the incidences of HAIs and the health burden and economic costs associated with them. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global infection control market during the forecast period 2020-2024, click here.
Competitive Landscape
With the presence of several major players, the global infection control market is moderately fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading infection control manufacturers, that include 3M Co., Astellas Pharma Inc., Cantel Medical Corp., Ecolab Inc., Getinge AB, GlaxoSmithKline Plc, Merck & Co. Inc., Mylan NV, Pfizer Inc., and Sanofi.
Also, the infection control market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.


グローバル市場調査データ販売概要

【レポートタイトル】感染対策の世界市場予測・分析:治療薬、非治療薬
【英語】Infection Control Market by Type and Geography - Forecast and Analysis 2020-2024

【発行日】2019年11月
【発行会社】Technavio
【商品コード】IRTNTR40140
【調査対象地域】グローバル
【販売サイト】GlobalResearch.jp

▼当市場調査データについて詳細内容・ご購入は下記ページへ▼
感染対策の世界市場予測・分析:治療薬、非治療薬...市場動向/規模/将来展望...



※当サイトのレポート紹介カバレッジ
■産業:医療、IT、電子、自動車、産業機械、建設、消費財、食品、化学、材料、エネルギー、金融、サービスなど多様
■地域:世界市場、アジア市場、中国市場、欧州市場、北米市場、中南米市場、中東市場、アフリカ市場など全世界
■レポート種類:市場動向、規模、占有率、トレンド、将来展望、未来予測、業界分析、産業分析、企業分析、事業機会分析、戦略提言など多様

【キーワード】

感染対策の世界市場予測・分析:治療薬、非治療薬、市場動向、市場規模、将来展望